Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Consult a qualified healthcare professional
In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
an orally delivered enzyme that finally reaches these hidden tissues could be its next chapter what I'd call an "ERT 3.0." Still preclinical, but a door well worth walking through
And reduced-dose maintenance strategies are showing real promise
Oct;17(10):970-6
US$ 28.85
US$ 26.22
US$ 27.46
